Home » Authors » Donna Young

Donna Young

Articles

ARTICLES

Adaptive Design Studies More Efficient, but Bias a Concern

Feb. 26, 2010

NIH, FDA Joining Hands in 'Microscope-to-Market' Plan

Feb. 25, 2010

FDA Panel Gives Solid Backing for Salix Cirrhosis Medication

Feb. 24, 2010

NIH Stem Cell Definition Change 'Hugely Important'

Feb. 23, 2010

FDA Raises Endpoint Concerns in Study of Salix Liver Drug

Feb. 23, 2010

NIH Amending Stem Cell Rules to Allow ACT Lines to Qualify

Feb. 22, 2010

XenoPort Shares Collapse After FDA Rejects RLS Compound

Feb. 19, 2010

Shares of XenoPort Inc. lost two-thirds of its value Thursday after the firm revealed that its partner GlaxoSmithKline plc had received a complete response letter from the FDA for its application for Horizant (gabapentin enacarbil), also known as GSK1838262 or XP13512, for moderate to severe primary restless legs syndrome (RLS). (BioWorld Today)

IP, Conflict of Interest Concerns Impede Collaborative Research

Feb. 18, 2010

As REMS Trend Grows, Drugmakers Seek Clarity

Feb. 17, 2010

Drug Lobbying Chief Tauzin Stepping Down from PhRMA

Feb. 16, 2010

View All Articles by Donna Young

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.